Evaluation of long-term toxicity after chemotherapy for testicular cancer

Journal of Clinical Oncology

Volumn 14, Issue 11, 1996, Pages 2923-2932

  Bokemeyer, C ^a   Berger, C C ^a   Kuczyk, M A ^a   Schmoll, H J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHOLESTEROL; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CREATININE; ESTRADIOL; ESTROGEN; ESTRONE; ETOPOSIDE; FOLLITROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; MAGNESIUM; PHOSPHATE; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE; VINBLASTINE; VINCA ALKALOID;

ADULT; ARTICLE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; OBESITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SALT LOSING NEPHRITIS; TESTIS CANCER;

EID: 0029805736     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.11.2923     Document Type: Article

References (48)

1. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumor with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
2. Bokemeyer C, Schmoll H-J, Harstrick A, et al: A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer 16:2225-2231, 1993
3. Coleman MP, Esteve J, Damiecki P, et al: Trends in Cancer Incidence and Mortality. Lyon, France, IARC, 1993
4. Berger CC, Bokemeyer C, Schuppert F, et al: Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73:1108-1114, 1996
5. Berger CC, Bokemeyer C, Schneider M, et al: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:2229-2238, 1995
6. Aass N, Kaasa S, Lund E, et al: Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer 61:151-155, 1990
7. Bissett D, Kunkeler L, Zwanenburg L, et al: Long-term sequelae of treatment for testicular germ cell tumor. Br J Cancer 62:655-659, 1990
8. Boyer M, Raghavan D, Harris PJ, et al: Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8:21-26, 1990
9. Moul JW, Robertson JE, George SL, et al: Complications of chemotherapy for testicular cancer. J Urol 142:1491-1496, 1989
10. Osanto S, Bukman A, Van Hoek F, et al: Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 10:574-579, 1992
11. Roth BJ, Einhorn LH, Greist A: Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin Oncol 15:345-350, 1988
12. Schwabe H-R, Herrmann R, Mathew M, et al: Langfristige Toxizitaet der Polychemotherapie bei kurativ behandeltem Hodenkarzinom. Dtsch Med Wochenschr 117:121-126, 1992
13. Stoter G, Koopman A, Vendrik CPJ, et al: Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 7:1099-1104, 1989
14. Stuart NSA, Woodroffe CM, Grundy R, et al: Long-term toxicity of chemotherapy for testicular cancer - The cost of cure. Br J Cancer 61:479-484, 1990
15. Hansen SW, Helweg-Larsen S, Trojaborg W: Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 7:1457-1461, 1989
16. Bokemeyer C, van Rhee J, Berger CC, et al: Peripheral neuropathy following cancer chemotherapy: long-term results in patients with curable neoplasms. Tumor Diagn Ther 14:232-237, 1993
17. Boyer M, Raghavan D: Toxicity of treatment of germ cell tumors. Semin Oncol 2:128-142, 1992
18. Gregg RW, Molepo JM, Monpetit VJA, et al: Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795-803, 1992
19. van der Hulst RJAM, Dreshler WA, Urbanus NAM: High-frequency audiometry in prospective clinical research of ototoxicity due to platinum derivates. Ann Otol Rhinol Laryngol 97:133-137, 1988
20. Blakley BW, Gupta AK, Myers SF, et al: Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 120:541-546, 1994
21. Gratton MA, Salvi RJ, Kamen B A, et al: Interaction of cisplatin and noise on the peripheral auditory system. Hear Res 50:211-223, 1990
22. Durrant JD, Rodgers G, Myers EN, et al: Hearing loss - Risk factor for cisplatin ototoxicity? Am J Otol 11:375-377, 1990
23. Barr-Hamilton RM, Matheson LM, Keay DG: Ototoxicity of cisplatin and its relationship to eye colour. J Laryngol Otol 105:7-11, 1991
24. Aguilar-Markulis NV, Beckley S, Priore R, et al: Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 16:111-123, 1981
25. Vermorken JB, Kapteijn TS, Hart AAM, et al: Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19:53-58, 1983
26. Teutsch C, Lipton A, Harvey HA: Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep 61:925-926, 1977
27. Vogelzang NJ, Bosl GJ, Johnson K: Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288-292, 1981
28. Hansen SW, Olsen N: Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold. J Clin Oncol 7:940-942, 1989
29. Scheulen ME, Schmidt CG: Raynaud-Syndrom nach kombinierter zytostatischer Behandlung von Patienten mit malignen Hodentumoren. Dtsch Med Wochenschr 107:1640-1644, 1982
30. Vogelzang NJ: Continuous infusion chemotherapy: A critical review. J Clin Oncol 2:1289-1304, 1984
31. Gerson R, Tellez Bernal E, Lazaro Leon M, et al: Low toxicity with continuous infusion of high-dose bleomycin in poor prognostic testicular cancer. Am J Clin Oncol 16:323-326, 1993
32. Bosl GJ, Geller NJ, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus VAB-6 (vinblastine + bleomycin + cisplatin + cyclophosphamide + actinomycin D) in patients with good prognosis germ cell tumor patients. J Clin Oncol 6:1231-1238, 1988
33. Hansen SW, Groth S, Daugaard G, et al: Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 6:1728-1731, 1988
34. Gietema JA, Sleijfer DTh, Willemse PHB, et al: Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 116:709-715, 1992
35. Stefenelli T, Kuzmits R, Ulrich W, et al: Acute vascular toxicity after combination chemotherapy with cisplatine, vinblastine and bleomycin for testicular cancer. Eur Heart J 9:552-556, 1988
36. Nichols CR, Roth BJ, Williams SD, et al: No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 10:760-765, 1992
37. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992
38. Ashraf M, Riggs JE, Wearden S, et al: Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynaecol Oncol 37:29-33, 1990
39. Regelson W, Loria R, Kalimi M: Dehydroepiandrosterone (DHEA)-The "mother steroid," Ann NY Acad Scie 719:553-563, 1994
40. Barrett-Connor E, Khaw K-T, Yen SSC: A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519-1524, 1986
41. Bokemeyer C, Schmoll HJ: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 9:1703-1709, 1993
42. Bokemeyer C, Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13:283-292, 1995
43. Nichols CR, Williams SD, Loehrer PJ: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 7:1163-1172, 1991
44. Georgiadis MS, Steinberg MS. Hankins LA, et al: Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst 87:361-366, 1995
45. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
46. Bokemeyer C, Schmoll H-J, Harms P, et al: Randomized comparison of cisplatin versus carboplatin combined with etoposide and bleomycin for minimal and moderate disease NSGCT. Onkologie 17:53, 1994 (suppl 2; abstr)
47. Mollmann JE, Glover DJ, Hogan WM, et al: Cisplatinumneuropathy. Risk factors, prognosis and protection by WR-2721. Cancer 61:2192-2195, 1988
48. Van der Hoop RG, Vecht CJ, van der Burg MEL, et al: Prevention of cisplatinum neuropathy with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 322:89-94, 1990